A 2022 report entitled ‘The U.S. Journey and Path Ahead’ provides perspective on where the US biosimilars industry stands today and what is expected in the future. The publication brought together the latest industry data on biosimilar utilization and payer coverage with survey data from healthcare providers, and thoughts from physicians and experts on biosimilars.
A large range of biosimilars of the anti-inflammatory drug Humira (adalimumab) are expected to flood the market in 2023. There could be as many as 10+ biosimilar competitors on the market by the end of 2023, based on current US Food and Drug Administration (FDA) approvals and pending applications .
This article provides a summary of newly approved biosimilars and an update on the biosimilar pipeline and those biosimilars in the approval process.
The National Commission for Markets and Competition (Commission Nacional de los Mercados y la Competencia, CNMC), the body that promotes and preserves the proper functioning of all markets in the interest of consumers and businesses in Spain, published on 22 June 2022 a study on the regulation of medicine prices in the country, which analyses its main problems and puts forward several recommendations to improve the functioning of the sector, including that of biosimilars, for the benefit of consumers and public health. The research focused on medicines sold through pharmacies.
After reviewing the key figures  and the incentive measures  to promote the use of biosimilars in France, Nadia Amer, speaker at BIOS 22 and Health Economics Analyst at Health Product Department of CNAM, presented the challenges that are faced and that leave still much room for improvement for biosimilar uptake in France .
During the presentation at BIOS 22, speaker Nadia Amer described the key figures of biosimilar medicines in France , and addressed the incentive measures promoting the use of biosimilar drugs, which have been implemented in France, mostly since 2018 .
At the online session of BIOS 22, Biosimilar medicines: changing patient care pathways, changing outcomes, speaker Nadia Amer, Health Economist Analyst at the Health Product Department in the Caisse Nationale d’Assurance Maladie (CNAM) in France, delivered a presentation based on concrete examples and experiences of biosimilar medicines in France .
Consumers in the US are overpaying for generics medicines by as much as 20%, a University of Southern California study reports . The white paper calls for transparency across the generic prescription drug supply chain and policies to increase competition and stop anti-competitive practices.
Dr Yow-Ming Wang provided welcoming remarks during the biosimilars webinar hosted by the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) and the U.S. Food and Drug Administration (FDA).
As the largest country in South America, Brazil is an important market for the pharmaceutical industry, but the biosimilars still represent less than 2% of the total biological drug market in the country .